JP2005505535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505535A5 JP2005505535A5 JP2003522539A JP2003522539A JP2005505535A5 JP 2005505535 A5 JP2005505535 A5 JP 2005505535A5 JP 2003522539 A JP2003522539 A JP 2003522539A JP 2003522539 A JP2003522539 A JP 2003522539A JP 2005505535 A5 JP2005505535 A5 JP 2005505535A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkyl
- methoxy
- optionally substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 4-amino-2-methylquinol-6-yl Chemical group 0.000 claims 488
- 125000001424 substituent group Chemical group 0.000 claims 90
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 81
- 125000000623 heterocyclic group Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 46
- 125000001309 chloro group Chemical group Cl* 0.000 claims 26
- 125000001153 fluoro group Chemical group F* 0.000 claims 26
- 125000003118 aryl group Chemical group 0.000 claims 24
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 22
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 125000001246 bromo group Chemical group Br* 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000005956 isoquinolyl group Chemical group 0.000 claims 10
- 125000005493 quinolyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 8
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 8
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 8
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 7
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004306 triazinyl group Chemical group 0.000 claims 6
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 5
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 5
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 5
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 4
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 4
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 4
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 3
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- KLAKUQBFAVTQQW-UHFFFAOYSA-N 4-quinolin-6-yl-2-N-(3,4,5-trimethoxyphenyl)-1H-pyrimidine-2,4-diamine Chemical compound N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C(=C1)OC)OC)OC)N KLAKUQBFAVTQQW-UHFFFAOYSA-N 0.000 claims 3
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 3
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 3
- FHGHVZKJXBLKMJ-UHFFFAOYSA-N 1-[2-methoxy-4-[[4-(quinolin-3-ylamino)pyrimidin-2-yl]amino]phenyl]-3-pyrrolidin-1-ylpropan-2-one Chemical compound COC1=CC(NC=2N=C(NC=3C=C4C=CC=CC4=NC=3)C=CN=2)=CC=C1CC(=O)CN1CCCC1 FHGHVZKJXBLKMJ-UHFFFAOYSA-N 0.000 claims 2
- ZCKCQAXSMORVJH-UHFFFAOYSA-N 1-[3,3-dimethyl-6-[[4-(quinolin-3-ylamino)pyrimidin-2-yl]amino]-2h-indol-1-yl]ethanone Chemical compound C1=CC=CC2=CC(NC=3C=CN=C(N=3)NC3=CC=C4C(C)(C)CN(C4=C3)C(=O)C)=CN=C21 ZCKCQAXSMORVJH-UHFFFAOYSA-N 0.000 claims 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 2
- IXSAPURSGZIKPM-UHFFFAOYSA-N 3-pyrimidin-4-ylquinoline Chemical compound C=1C2=CC=CC=C2N=CC=1C1=CC=NC=N1 IXSAPURSGZIKPM-UHFFFAOYSA-N 0.000 claims 2
- DTJAPEZIABVQFP-UHFFFAOYSA-N 4-isoquinolin-3-yl-2-N-(3,4,5-trimethoxyphenyl)-1H-pyrimidine-2,4-diamine Chemical compound C1=NC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C(=C1)OC)OC)OC)N DTJAPEZIABVQFP-UHFFFAOYSA-N 0.000 claims 2
- FHDPQTHZTKXVCW-UHFFFAOYSA-N 4-n-quinolin-3-yl-2-n-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3C=C4C=CC=CC4=NC=3)C=CN=2)=C1 FHDPQTHZTKXVCW-UHFFFAOYSA-N 0.000 claims 2
- GYBIWXCHCBTGJZ-UHFFFAOYSA-N CC1=C(C=C(C(=C1)OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC(F)(F)F)N Chemical compound CC1=C(C=C(C(=C1)OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC(F)(F)F)N GYBIWXCHCBTGJZ-UHFFFAOYSA-N 0.000 claims 2
- FHTUWMWXFOIMDW-UHFFFAOYSA-N CC1=C(C=C(C(=C1)OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC)N Chemical compound CC1=C(C=C(C(=C1)OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC)N FHTUWMWXFOIMDW-UHFFFAOYSA-N 0.000 claims 2
- ZSMVHKNVAMTQBY-UHFFFAOYSA-N CN(CCC=1C=C(C=CC=1OC)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N)C Chemical compound CN(CCC=1C=C(C=CC=1OC)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N)C ZSMVHKNVAMTQBY-UHFFFAOYSA-N 0.000 claims 2
- MGTZKLAOVGADEY-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N MGTZKLAOVGADEY-UHFFFAOYSA-N 0.000 claims 2
- NURDJTYBHTXJAJ-UHFFFAOYSA-N COC=1C=C(C=C(C=1OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC(F)(F)F)N Chemical compound COC=1C=C(C=C(C=1OC)OC)C1(NC=CC(=N1)NC=1C=NC2=CC=C(C=C2C=1)OC(F)(F)F)N NURDJTYBHTXJAJ-UHFFFAOYSA-N 0.000 claims 2
- GPBYUURBWXNIHP-UHFFFAOYSA-N COC=1C=C(C=CC=1C1=CN=CO1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N Chemical compound COC=1C=C(C=CC=1C1=CN=CO1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N GPBYUURBWXNIHP-UHFFFAOYSA-N 0.000 claims 2
- SOFYNOMCXZXSKJ-UHFFFAOYSA-N N1(CCCCC1)CCOC1=CC=C(C=C1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N Chemical compound N1(CCCCC1)CCOC1=CC=C(C=C1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N SOFYNOMCXZXSKJ-UHFFFAOYSA-N 0.000 claims 2
- YSDAQRLYNAQAKT-UHFFFAOYSA-N N1(CCOCC1)C1=CC=C(C=N1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N Chemical compound N1(CCOCC1)C1=CC=C(C=N1)C1(NC=CC(=N1)NC=1C=NC2=CC=CC=C2C=1)N YSDAQRLYNAQAKT-UHFFFAOYSA-N 0.000 claims 2
- UHEGWXNCIOAGLJ-UHFFFAOYSA-N O1C=NC=C1C=1C=C(C=CC=1)C1(NC=CC(=N1)NC=1C=C2C=CC=NC2=CC=1)N Chemical compound O1C=NC=C1C=1C=C(C=CC=1)C1(NC=CC(=N1)NC=1C=C2C=CC=NC2=CC=1)N UHEGWXNCIOAGLJ-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- KUMNUQZUSIYYSI-UHFFFAOYSA-N 2-N,4-di(quinolin-3-yl)-1H-pyrimidine-2,4-diamine Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC=1C=NC2=CC=CC=C2C=1)N KUMNUQZUSIYYSI-UHFFFAOYSA-N 0.000 claims 1
- RTOWKQKISNDKSF-UHFFFAOYSA-N 2-N-(3,4-dimethoxyphenyl)-4-quinolin-3-yl-1H-pyrimidine-2,4-diamine Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C=C1)OC)OC)N RTOWKQKISNDKSF-UHFFFAOYSA-N 0.000 claims 1
- ZXYZQVYSFPTDKJ-UHFFFAOYSA-N 2-N-(3,4-dimethoxyphenyl)-4-quinolin-6-yl-1H-pyrimidine-2,4-diamine Chemical compound N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C=C1)OC)OC)N ZXYZQVYSFPTDKJ-UHFFFAOYSA-N 0.000 claims 1
- UTXOVTTZSJPSAB-UHFFFAOYSA-N 2-N-(4,5-dimethoxy-2-methylphenyl)-4-isoquinolin-3-yl-1H-pyrimidine-2,4-diamine Chemical compound C1=NC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=C(C=C(C(=C1)OC)OC)C)N UTXOVTTZSJPSAB-UHFFFAOYSA-N 0.000 claims 1
- UYFHSODLLKSDLA-UHFFFAOYSA-N 2-N-quinolin-3-yl-4-quinolin-6-yl-1H-pyrimidine-2,4-diamine Chemical compound N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC=1C=NC2=CC=CC=C2C=1)N UYFHSODLLKSDLA-UHFFFAOYSA-N 0.000 claims 1
- WPLNQGXOVZEUGW-UHFFFAOYSA-N 2-n-(3,5-dimethoxyphenyl)-4-n-quinolin-3-ylpyrimidine-2,4-diamine Chemical compound COC1=CC(OC)=CC(NC=2N=C(NC=3C=C4C=CC=CC4=NC=3)C=CN=2)=C1 WPLNQGXOVZEUGW-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- NNWLZTUCSATJMM-UHFFFAOYSA-N 3-[[4-(naphthalen-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(NC=2N=C(NC=3C=C4C=CC=CC4=CC=3)C=CN=2)=C1 NNWLZTUCSATJMM-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- JKNBRHLJJZABQI-UHFFFAOYSA-N 4-(1-methoxyisoquinolin-3-yl)-2-N-(3,4,5-trimethoxyphenyl)-1H-pyrimidine-2,4-diamine Chemical compound COC1=NC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C(=C1)OC)OC)OC)N JKNBRHLJJZABQI-UHFFFAOYSA-N 0.000 claims 1
- RVJYDFFHLBJSDN-UHFFFAOYSA-N 4-(2-methylquinolin-6-yl)-2-N-(3,4,5-trimethoxyphenyl)-1H-pyrimidine-2,4-diamine Chemical compound CC1=NC2=CC=C(C=C2C=C1)C1(NC(=NC=C1)NC1=CC(=C(C(=C1)OC)OC)OC)N RVJYDFFHLBJSDN-UHFFFAOYSA-N 0.000 claims 1
- NQXFNEZBLNNBMG-UHFFFAOYSA-N 4-quinolin-3-yl-2-N-quinolin-6-yl-1H-pyrimidine-2,4-diamine Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC=1C=C2C=CC=NC2=CC=1)N NQXFNEZBLNNBMG-UHFFFAOYSA-N 0.000 claims 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- WOXOVAQJUXBBRF-UHFFFAOYSA-N COC1=CC=CC=C1NC2=NC(C=CN2)(C3=CC4=C(C=C3)N=CC=C4)N Chemical compound COC1=CC=CC=C1NC2=NC(C=CN2)(C3=CC4=C(C=C3)N=CC=C4)N WOXOVAQJUXBBRF-UHFFFAOYSA-N 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- DGYZYDBDRVDHOG-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=C(C=CC=C1)OC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=C(C=CC=C1)OC)N DGYZYDBDRVDHOG-UHFFFAOYSA-N 0.000 claims 1
- BDRUTAVXYHDDGQ-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C=C1)OCC)OCC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=C(C=C1)OCC)OCC)N BDRUTAVXYHDDGQ-UHFFFAOYSA-N 0.000 claims 1
- NLWGLKDJSAVSBW-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)CC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)CC)N NLWGLKDJSAVSBW-UHFFFAOYSA-N 0.000 claims 1
- BQSKJVFWYMZGRC-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N BQSKJVFWYMZGRC-UHFFFAOYSA-N 0.000 claims 1
- QXZUIBKAJXYEDP-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC=C(C=C1)CC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC=C(C=C1)CC)N QXZUIBKAJXYEDP-UHFFFAOYSA-N 0.000 claims 1
- LAIHLKXCOKOYRT-UHFFFAOYSA-N N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC=C(C=C1)OC)N Chemical compound N1=CC(=CC2=CC=CC=C12)C1(NC(=NC=C1)NC1=CC=C(C=C1)OC)N LAIHLKXCOKOYRT-UHFFFAOYSA-N 0.000 claims 1
- UZFDBHWGYIHVMN-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)CC)N Chemical compound N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)CC)N UZFDBHWGYIHVMN-UHFFFAOYSA-N 0.000 claims 1
- NFOYPTWJZYQJSG-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N Chemical compound N1=CC=CC2=CC(=CC=C12)C1(NC(=NC=C1)NC1=CC(=CC=C1)OC)N NFOYPTWJZYQJSG-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 1
- 0 **Nc1nccc(NCc2cc(C=C**3)c3cc2)n1 Chemical compound **Nc1nccc(NCc2cc(C=C**3)c3cc2)n1 0.000 description 7
- GHCFWKFREBNSPC-UHFFFAOYSA-N Cc1nc(N)ncc1 Chemical compound Cc1nc(N)ncc1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31433901P | 2001-08-22 | 2001-08-22 | |
| US10/225,783 US6939874B2 (en) | 2001-08-22 | 2002-08-21 | Substituted pyrimidinyl derivatives and methods of use |
| PCT/US2002/026870 WO2003018021A1 (en) | 2001-08-22 | 2002-08-22 | 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505535A JP2005505535A (ja) | 2005-02-24 |
| JP2005505535A5 true JP2005505535A5 (https=) | 2006-01-05 |
Family
ID=26919901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003522539A Pending JP2005505535A (ja) | 2001-08-22 | 2002-08-22 | 抗癌剤として使用するための２，４−二置換ピリミジニル誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6939874B2 (https=) |
| EP (1) | EP1427421A1 (https=) |
| JP (1) | JP2005505535A (https=) |
| AU (1) | AU2002336390B2 (https=) |
| CA (1) | CA2457838A1 (https=) |
| MX (1) | MXPA04001623A (https=) |
| PL (1) | PL370041A1 (https=) |
| WO (1) | WO2003018021A1 (https=) |
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040062557A (ko) * | 2001-11-01 | 2004-07-07 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| ES2445208T3 (es) * | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| OA13309A (en) | 2002-12-20 | 2007-04-13 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| RU2400477C2 (ru) * | 2003-03-14 | 2010-09-27 | Новартис Аг | 2,4-ди(фениламино)пиримидины, применимые при лечении неопластических заболеваний, воспалительных нарушений и нарушений иммунной системы |
| US7201779B2 (en) | 2003-06-16 | 2007-04-10 | L'oreal S.A. | Dye composition comprising at least one direct dye containing mixed chromophores |
| US7172633B2 (en) | 2003-06-16 | 2007-02-06 | L'ORéAL S.A. | Lightening dye composition comprising at least one cationic direct dye containing mixed chromophores |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| BRPI0413018B8 (pt) * | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, e, uso de um composto |
| NZ585188A (en) * | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| MXPA06003054A (es) * | 2003-09-18 | 2006-05-31 | Novartis Ag | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. |
| US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
| KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
| JP4932495B2 (ja) * | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| US7288121B2 (en) | 2004-02-27 | 2007-10-30 | L'oreal S.A. | Composition comprising at least one mixed dye comprising at least one chromophore chosen from compounds of the methine family and/or the carbonyl family, dyeing process and kit, and mixed dyes |
| US7303591B2 (en) | 2004-02-27 | 2007-12-04 | L'oreal S.A. | Composition comprising at least one mixed dye comprising at least two chromophores of (hetero) aromatic nitro or cyclic azine type, dyeing process, and mixed dyes |
| US7300471B2 (en) | 2004-02-27 | 2007-11-27 | L'oreal S.A. | Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes. |
| TWI378934B (en) * | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| MXPA06013165A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| BRPI0514094A (pt) | 2004-08-02 | 2008-05-27 | Osi Pharm Inc | composto, composição, e, método de tratamento de distúrbio hiperproliferativo |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| MX2007004488A (es) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos. |
| EP1814878B1 (en) * | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| AU2005322855B2 (en) * | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| JP2008534481A (ja) * | 2005-03-23 | 2008-08-28 | アストラゼネカ アクチボラグ | インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン |
| SI1869032T1 (sl) * | 2005-04-05 | 2008-12-31 | Astrazeneca Ab | Pirimidinski derivati za uporabo kot sredstva proti raku |
| GB0506886D0 (en) * | 2005-04-05 | 2005-05-11 | Astrazeneca Ab | Chemical compounds |
| GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
| DE102005016634A1 (de) * | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| MX2008000574A (es) * | 2005-07-11 | 2008-03-14 | Sanofi Aventis | Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk. |
| FR2888239B1 (fr) * | 2005-07-11 | 2008-05-09 | Sanofi Aventis Sa | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
| FR2889954B1 (fr) | 2005-08-26 | 2007-10-19 | Oreal | Colorants mixtes cationiques comprenant un chromophore anthraquinone et leur utilisation en colorant capillaire |
| US20090306116A1 (en) * | 2005-09-16 | 2009-12-10 | Astrazeneca Ab | Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| TW200736232A (en) * | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| RU2008152195A (ru) * | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
| WO2007146977A1 (en) | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| EP2089369B1 (en) | 2006-10-19 | 2011-02-02 | Rigel Pharmaceuticals, Inc. | 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
| CN101535276B (zh) | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| EP2311807B1 (en) | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| WO2008117051A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | S-6-meth0xy-2- (2- (3- (pyrimid-2-yl) is0xaz0l-5-yl) pyrrolidin-1-yl) -4- (5-methyl-ih-pyrazol-s-ylamino) pyrimidine and polymorphic forms thereof as modulators of the insulin-like growth |
| WO2009010794A1 (en) * | 2007-07-19 | 2009-01-22 | Astrazeneca Ab | 2,4-diamino-pyrimidine derivatives |
| AU2008289101A1 (en) * | 2007-08-17 | 2009-02-26 | Icagen, Inc. | Heterocycles as potassium channel modulators |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| EA017252B1 (ru) * | 2007-08-28 | 2012-11-30 | Айрм Ллк | Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ |
| EP2247596A2 (en) | 2008-01-11 | 2010-11-10 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| WO2010072155A1 (zh) * | 2008-12-26 | 2010-07-01 | 复旦大学 | 一种嘧啶类衍生物及其制备方法和用途 |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010123792A1 (en) | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Preparation of c-pyrazine-methylamines |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| EP2427192A1 (en) * | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
| MX2011012632A (es) * | 2009-05-27 | 2012-03-06 | Abbott Lab | Inhibidores de actividad de cinasa tipo pirimidina. |
| KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| WO2010144394A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| CN102470135A (zh) * | 2009-07-28 | 2012-05-23 | 里格尔药品股份有限公司 | 抑制jak途径的组合物和方法 |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20130137709A1 (en) * | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| CN105566229A (zh) | 2010-08-10 | 2016-05-11 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐及其用途和制备方法 |
| EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| MX382354B (es) | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| PL2825042T3 (pl) | 2012-03-15 | 2019-02-28 | Celgene Car Llc | Sole inhibitora kinazy receptora czynnika wzrostu naskórka |
| US8993614B2 (en) * | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| AU2014214846A1 (en) | 2013-02-08 | 2015-07-23 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| JP6255038B2 (ja) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | 癌治療 |
| MX394360B (es) * | 2013-03-14 | 2025-03-24 | Sumitomo Pharma Oncology Inc | Inhibidores de jak2 y alk2 y metodos para su uso. |
| WO2014152716A1 (en) * | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| EP3057955B1 (en) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| CA2954764A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| CN105601573B (zh) * | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP3347018B1 (en) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| KR102644934B1 (ko) | 2016-11-11 | 2024-03-08 | 새지메트 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절인자 |
| EP3675860B1 (en) * | 2017-08-28 | 2023-03-08 | Zhihong, Chen | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof |
| CN112533602A (zh) | 2018-04-05 | 2021-03-19 | 大日本住友制药肿瘤公司 | Axl激酶抑制剂及其用途 |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
| CN111362928A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物 |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| CN112513029B (zh) * | 2019-06-21 | 2023-10-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
| CN115515589A (zh) * | 2020-02-14 | 2022-12-23 | 萨克生物研究学院 | Ulk1/2抑制剂及其使用方法 |
| CN113549018B (zh) * | 2020-04-24 | 2024-02-27 | 中国药科大学 | 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| KR102560221B1 (ko) * | 2021-02-24 | 2023-07-27 | 서울대학교산학협력단 | 멀티키나제 억제제 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| KR102939283B1 (ko) * | 2022-05-03 | 2026-03-13 | 한국화학연구원 | 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN115141150B (zh) * | 2022-07-25 | 2024-04-26 | 南通大学 | 2,4,5-三取代嘧啶羟胺酰衍生物及其制备方法与应用 |
| WO2025030163A1 (en) * | 2023-08-02 | 2025-02-06 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of igf-1r for treatment of disease |
| KR20250041906A (ko) * | 2023-09-19 | 2025-03-26 | (주)엠디바이오팜 | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB663097A (en) | 1948-11-05 | 1951-12-19 | Charles Henry Vasey | Manufacture of quaternary salts |
| BE492034A (https=) | 1948-11-05 | |||
| BE492033A (https=) | 1948-11-05 | |||
| GB696692A (en) | 1950-12-06 | 1953-09-09 | Ici Ltd | New quinazoline derivatives |
| GB794043A (en) | 1955-06-03 | 1958-04-30 | Ici Ltd | New quinoline derivatives |
| HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
| US5043317A (en) | 1990-12-14 | 1991-08-27 | Eastman Kodak Company | Yellow dye mixture for thermal color proofing |
| GB9309573D0 (en) | 1993-05-10 | 1993-06-23 | Merck Sharp & Dohme | Therapeutic agents |
| TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| DE19750701A1 (de) | 1997-11-15 | 1999-05-20 | Dystar Textilfarben Gmbh & Co | Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren |
| AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| CZ299380B6 (cs) | 1998-03-27 | 2008-07-09 | Janssen Pharmaceutica N. V. | Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující |
| HRP20080359B1 (hr) | 1998-11-10 | 2016-01-01 | Janssen Pharmaceutica N.V. | PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1409487A1 (en) | 1999-09-15 | 2004-04-21 | Warner-Lambert Company Llc | Pteridinones as kinase inhibitors |
| CA2384188C (en) | 1999-09-24 | 2008-06-17 | Janssen Pharmaceutica N.V. | Antiviral compositions |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| SK7402002A3 (en) * | 1999-11-29 | 2002-11-06 | Aventis Pharma Sa | Arylamine derivatives and their use as anti-telomerase agent |
| CA2394727A1 (en) | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| US6977259B2 (en) * | 2000-01-28 | 2005-12-20 | Astrazeneca Ab | Quinoline derivatives and their use as aurora 2 kinase inhibitors |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1274705A1 (en) | 2000-03-29 | 2003-01-15 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US20020111353A1 (en) | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| AU2002228922A1 (en) | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| EP1341788B1 (en) | 2000-12-15 | 2005-08-10 | Glaxo Group Limited | Pyrazolopyridines |
| DE60112330T2 (de) | 2000-12-15 | 2006-04-13 | Glaxo Group Ltd., Greenford | Pyrazolopyridinderivate |
| EP1343782B1 (en) | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
-
2002
- 2002-08-21 US US10/225,783 patent/US6939874B2/en not_active Expired - Fee Related
- 2002-08-22 PL PL02370041A patent/PL370041A1/xx not_active Application Discontinuation
- 2002-08-22 EP EP02773237A patent/EP1427421A1/en not_active Withdrawn
- 2002-08-22 WO PCT/US2002/026870 patent/WO2003018021A1/en not_active Ceased
- 2002-08-22 MX MXPA04001623A patent/MXPA04001623A/es active IP Right Grant
- 2002-08-22 CA CA002457838A patent/CA2457838A1/en not_active Abandoned
- 2002-08-22 AU AU2002336390A patent/AU2002336390B2/en not_active Ceased
- 2002-08-22 JP JP2003522539A patent/JP2005505535A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505535A5 (https=) | ||
| CN101641093B (zh) | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 | |
| CA2620034C (en) | Diaminopyrimidines as p2x3 and p2x2/3 modulators | |
| ES2726882T3 (es) | Derivados de tienopirimidina que tienen actividad inhibidora para la proteína cinasa | |
| RU2217142C2 (ru) | Химические соединения | |
| ES3036467T3 (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
| US6716851B2 (en) | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | |
| RU2625799C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ | |
| CN110072528B (zh) | 治疗肿瘤的药物组合物 | |
| CN103857288A (zh) | 作为激酶抑制剂的氨基-喹啉 | |
| ES2400695T3 (es) | Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38 | |
| JP2006520805A5 (https=) | ||
| CA2403514A1 (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| CA2685219A1 (en) | Diazaquinolones that inhibit prolyl hydroxylase activity | |
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| WO2013156869A1 (en) | Treatment of diseases by epigenetic regulation | |
| WO2011093684A2 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | |
| RU2008145225A (ru) | Соединения индазола и способы ингибирования cd7 | |
| ZA200405908B (en) | Quinazoline compounds | |
| JP2007529486A5 (https=) | ||
| CA2425268A1 (en) | Pyridinone derivatives for treatment of atherosclerosis | |
| KR20160017039A (ko) | 헤테로사이클 유도체 및 그의 용도 | |
| JP2013523657A (ja) | キナーゼ阻害剤としてのインダゾリル‐ピリミジン | |
| WO2002019975A1 (fr) | Stimulants de la croissance des cheveux | |
| TW201040159A (en) | Novel compound having 4-pyridylalkylthio group as substituent |